Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI9GC3
|
|||
| Drug Name |
AC0682
|
|||
| Drug Type |
PROTAC
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1 | [1] | |
| Company |
Accutar Biotechnology
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05489679) A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Accutar Biotechnology | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.